<DOC>
	<DOCNO>NCT01012739</DOCNO>
	<brief_summary>This study assess efficacy , safety , tolerability , pharmacokinetics two different formulation indacaterol , one administer via Concept1 device one administer via Simoon device . The study aim determine whether novel formulation ( Simoon ) similar profile establish formulation ( Concept1 ) .</brief_summary>
	<brief_title>Efficacy , Safety , Tolerability , Pharmacokinetics Indacaterol Maleate Via Concept1 Simoon Devices</brief_title>
	<detailed_description>This study double-blind regard Concept1 , placebo lactose-blended indacaterol available . However , regard Simoon , neither subject investigator blind due lack placebo PulmoSphere formulation . Hence , overall designation study partially-blind .</detailed_description>
	<mesh_term>Maleic acid</mesh_term>
	<criteria>Inclusion criterion : Patients persistent asthma forced expiratory volume 1 second ( FEV1 ) â‰¥ 50 % Patients use inhaled corticosteroid ( without longacting beta agonist ) Exclusion criterion : Asthma exacerbation previous 6 month Chronic obstructive pulmonary disease ( COPD ) pulmonary disease Excessive use shortacting beta agonist Other protocoldefined inclusion/exclusion criterion apply study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>asthma</keyword>
	<keyword>QAB149</keyword>
	<keyword>indacaterol</keyword>
	<keyword>pulmonary function</keyword>
</DOC>